Astrazeneca Terminates License Agreement With Map Pharmaceuticals
Published: 09-Jul-2009
UDB trial failed to meet its primary endpoints
AstraZeneca has terminated the license agreement with MAP Pharmaceuticals, regarding Unit Dose Budesonide (UDB).
UDB, an investigational treatment for paediatric asthma, was the subject of an initial phase-III clinical trial conducted by MAP Pharmaceuticals. On February 23, 2009, MAP announced that the trial failed to meet its primary endpoints.
In light of the clinical trial results, AstraZeneca exercised its right to terminate the license agreement and expects to record an impairment charge of $44 million in the second quarter results.
AstraZeneca is engaged in the research, development, manufacturing and marketing of prescription medicines and supplier for healthcare services. It is focused in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.
MAP Pharmaceuticals is dedicated to developing and commercialising new therapies for children and adults suffering from chronic conditions.
Network Sites

Suppliers To This Sector
Browse A-Z
World Courier
Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry...
WebWise Learning
Turning Information into Working Knowledge ...
Vetter Pharma International
High-Quality Aseptically Pre-Filled Injection Systems, Cartridges and Vials ...
Valsynthese
Hazardous Chemistry in Safe Hands ...
USB
Products from Affymetrix ...
Umicore Precious Metals Chemistry
Chemicals and Catalysts for Industrial Applications ...
White Papers
Browse A-Z
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model
Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
Enabling Drug Delivery Deal Making
Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...
Automating Training Control Processes to Comply with FDA Requirements
Well-managed training programs minimize the risk of non-compliance and improve product qua ...
TNO Pharma Services: From Discovery to the Clinic
Our kinetics & metabolism experts can help you select and further develop your candidate d ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully